FTXH — First Trust Nasdaq Pharmaceuticals ETF
Data updated: 2026-08-21
FTXH — First Trust Nasdaq Pharmaceuticals ETF. United States Large Cap Blend / Core Health Care Equity. Holdings, fees, performance and SEC filings.
FTXH Fund Overview
FTXH — First Trust Nasdaq Pharmaceuticals ETF is a US ETF managed by First Trust Exchange-Traded Fund VI, categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: First Trust Exchange-Traded Fund VI
- Category: United States Large Cap Blend / Core Health Care Equity
- Assets under management: $36.24M
- 1-year return: 50.8%
- Ticker: FTXH
- SEC CIK: 0001552740
- SEC series ID: S000053945
- Share class ID: C000169747
FTXH Holdings
Top 10 holdings of First Trust Nasdaq Pharmaceuticals ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Company | 7.77% |
| Abbvie, Inc. | 7.39% |
| Merck & Company, Inc. | 7.07% |
| Johnson & Johnson | 6.96% |
| Bristol-Myers Squibb Company | 6.29% |
| Biogen, Inc. | 3.84% |
| Viatris, Inc. | 3.62% |
| Cardinal Health, Inc. | 3.53% |
| Vertex Pharmaceuticals, Inc. | 3.41% |
| Amgen, Inc. | 3.18% |
FTXH Portfolio Allocation
Asset-class allocation of First Trust Nasdaq Pharmaceuticals ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 0.1% |
FTXH Performance
Total returns for FTXH (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 16.3% |
| 1 year | 50.8% |
| 3 years (annualised) | 15.0% |
| 5 years (annualised) | 9.6% |
FTXH Risk Information
Risk metrics for FTXH, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 14.4%
FTXH Costs and Fees
FTXH costs about $60 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.60%
- Gross expense ratio: 0.60%
- Portfolio turnover: 35%
- Brokerage commissions: 1.40 bps of average net assets (SEC N-CEN)
FTXH Cashflows
Over the 12 months to 2026-06, First Trust Nasdaq Pharmaceuticals ETF had net inflows of $13.38M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | −$1.78M |
| 2026-05 | $1.73M |
| 2026-04 | $3.36M |
| 2026-03 | $0 |
| 2026-02 | $5.25M |
| 2026-01 | $1.69M |
FTXH Debt Constituents
No individual debt constituents are reported in First Trust Nasdaq Pharmaceuticals ETF's latest SEC N-PORT filing.
FTXH Prospectus and SEC Filings
Official First Trust Nasdaq Pharmaceuticals ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-07-29
- Prospectus (485BPOS) — filed 2025-07-29
- Prospectus (485BPOS) — filed 2024-07-29
- Portfolio holdings (N-PORT) — filed 2026-08-21
- Portfolio holdings (N-PORT) — filed 2026-05-21
- Portfolio holdings (N-PORT) — filed 2026-02-25
- Annual census (N-CEN) — filed 2026-06-10
- Annual census (N-CEN) — filed 2025-06-12
Related Funds
Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.